Selvarajah Viknesh, Pasea Laura, Ojha Sanjay, Wilkinson Ian B, Tomlinson Laurie A
Clinical Pharmacology Unit, Department of Medicine, University of Cambridge, Cambridge, United Kingdom ; Department of Nephrology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Centre for Applied Medical Statistics, Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom.
PLoS One. 2014 Jan 28;9(1):e86514. doi: 10.1371/journal.pone.0086514. eCollection 2014.
Systolic blood pressure variability is an independent risk factor for mortality and cardiovascular events. Standard measures of blood pressure predict outcome poorly in haemodialysis patients. We investigated whether systolic blood pressure variability was associated with mortality in incident haemodialysis patients. We performed a longitudinal observational study of patients commencing haemodialysis between 2005 and 2011 in East Anglia, UK, excluding patients with cardiovascular events within 6 months of starting haemodialysis. The main exposure was variability independent of the mean (VIM) of systolic blood pressure from short-gap, pre-dialysis blood pressure readings between 3 and 6 months after commencing haemodialysis, and the outcome was all-cause mortality. Of 203 patients, 37 (18.2%) patients died during a mean follow-up of 2.0 (SD 1.3) years. The age and sex-adjusted hazard ratio (HR) for mortality was 1.09 (95% confidence interval (CI) 1.02-1.17) for a one-unit increase of VIM. This was not altered by adjustment for diabetes, prior cardiovascular disease and mean systolic blood pressure (HR 1.09, 95% CI 1.02-1.16). Patients with VIM of systolic blood pressure above the median were 2.4 (95% CI 1.17-4.74) times more likely to die during follow-up than those below the median. Results were similar for all measures of blood pressure variability and further adjustment for type of dialysis access, use of antihypertensives and absolute or variability of fluid intake did not alter these findings. Diastolic blood pressure variability showed no association with all cause mortality. Our study shows that variability of systolic blood pressure is a strong and independent predictor of all-cause mortality in incident haemodialysis patients. Further research is needed to understand the mechanism as this may form a therapeutic target or focus for management.
收缩压变异性是死亡率和心血管事件的独立危险因素。血压的标准测量方法在血液透析患者中对预后的预测效果不佳。我们调查了收缩压变异性是否与初发血液透析患者的死亡率相关。我们对2005年至2011年在英国东安格利亚开始进行血液透析的患者进行了一项纵向观察性研究,排除了开始血液透析后6个月内发生心血管事件的患者。主要暴露因素是血液透析开始后3至6个月期间,短间隔、透析前血压读数中独立于收缩压均值的变异性(VIM),结局为全因死亡率。在203例患者中,37例(18.2%)患者在平均2.0(标准差1.3)年的随访期间死亡。VIM每增加一个单位,年龄和性别校正后的死亡风险比(HR)为1.09(95%置信区间(CI)1.02 - 1.17)。在对糖尿病、既往心血管疾病和平均收缩压进行校正后,这一结果未发生改变(HR 1.09,95% CI 1.02 - 1.16)。收缩压VIM高于中位数的患者在随访期间死亡的可能性是低于中位数患者的2.4(95% CI 1.17 - 4.74)倍。所有血压变异性测量结果均相似,进一步对透析通路类型、抗高血压药物的使用以及液体摄入量的绝对值或变异性进行校正,并未改变这些结果。舒张压变异性与全因死亡率无关联。我们的研究表明,收缩压变异性是初发血液透析患者全因死亡率的一个强有力的独立预测因素。需要进一步研究以了解其机制,因为这可能成为一个治疗靶点或管理重点。